Clinical Trial Update: An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

View source ↗

Summary

Observational study assessing outcomes for relapsing-remitting MS patients who start or restart baseline interferon beta-1a after prior escalation with mitoxant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Interferon beta-1a (Avonex) (interferon beta-1a)
• Mitoxantrone (Novantrone) (mitoxantrone)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing-Remitting Multiple Sclerosis | Status: COMPLETED